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Summary.-In a retrospective study the postoperative time courses of CEA in
colorectal cancer patients with recurrent disease were analysed. In87/114 cases with
increasing concentrations of circulating CEA under close follow-up a linear
relationship between log CEA and time could be established during disease
recurrence. The individual doubling times of the serum CEA concentration in the log
CEA period were calculated and found to cover distinct ranges dependent on the
diagnosis of disease recurrence. The CEA doubling times concomitant with local
recurrence or second primary carcinomas ranged from 142 to 868 days, visceral
metastasis other than liver metastasis from 47 to 231 days and liver metastasis from
10 to 102 days. Patients with bone metastases exhibited CEA doubling times of 54-60
days and a patient with brain metastasis had a CEA doubling time of 598 days. The
CEA doubling times of patients with liver metastasis and no further treatment,
correlated well with the time of survival after the initial CEA increase of the log CEA
phase (r=0-870, n=33). The mean survival expressed in multiples of the individual
CEA doubling times was 7-0+118. Patients with liver metastasis who underwent
various treatments of recurrent disease had a distinctly longer mean survival of
17-4+9-4 CEA doubling times (P<0-001). CEA doubling times can be used as a
potential method to assess the efficacy of various treatments.
POSTOPERATIVE MONITORING ofcirculating
carcinoembryonic antigen (CEA) in
patients with resected colorectal cancer is
often used for the early detection of
recurrent cancer.Consecutively rising CEA
concentrations in the blood generally
reflect disease recurrence and the rates of
increase of the CEA concentrations can be
used to discriminate between localized
recurrence and metastatic spread (Staab et
al., 1978; Wood et al., 1980; Steele et al.,
1980).
A more precise characterization of the
rate ofCEA increase in relation to tumour
development is indicated in recent studies
of xenotransplants into nude mice using
CEA-releasing human colorectal tumour
cell lines. Tumour growth correlated well
with a concomitant increase of circulating
CEA during the logarithmic growth phase
but showed a marked dissociation when
the tumour growth rate slowed down. The
rate of CEA increase during the logarith-
mic growth phase of the tumour allowed
the doubling time of the serum CEA
concentration to be calculated (Staab &
Anderer, 1981, 1982). Similar findings were
reported for nude mice xenografted with
alpha-fetoprotein (AFP)-producinghuman
teratomas (Raghavan et al., 1980).
The doubling time of a circulating
tumour marker appears to have a prog-
nostic value since the rate of increase of
circulating AFP in patients with hepato-
cellular carcinoma was exponential and
the AFP doubling times correlated posi-
tively with the survival of the patients
(Johnson & Williams, 1980).
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In the present study we examined
retrospectively the postoperative CEA
time courses of colorectal cancer patients
with recurrent disease who have been
registered since 1974. The aim ofthe study
was to establish increases of circulating
CEA which exhibit a linear relationship
between log CEA and time, to calculate
CEA doubling times for the periods of
logarithmic CEA increase and to correlate
CEA doubling times with diagnosis of
disease recurrence and survival of the
patients.
PATIENTS AND METHODS
Patieits.-During the routine postopera-
tive follow-up of patients with resected
primary colorectal carcinoma, which included
serum CEA determination and clinical exam-
ination every 2-3 months, we recorded 114
patients with recurrent disease who could be
closely followed up. In most cases (87/114)
the patients exhibited a distinct phase of
logarithmic increase of circulating CEA
during disease recurrence, in 21/114 patients
the CEA time course was not logarithmical or
was not well established due to partly missing
CEA determinations and 6/114 patients were
CEA-niegative throughout the entire surveil-
lance.
Diagnosis ofrecurrence and metastasis was
established clinically by endoscopy, radio-
logical investigations, radioisotopic scanning,
sonography and computerized tomography,
or by explorative laparotomy or second-look
surgery. Liver metastases generally appeared
within 12 months after primary resection. At
the time of diagnosis of metastases the
patients were free of any complaints. Some of
the patients received treatment with 5-
fluorouracil (5-FU), ftorafur, or a combina-
tion of vincristine, adriblastin and 1,3-bis(2-
chloroethyl-1-nitrosourea) (BCNU) or 5-FU;
others underwent second-look surgery and/or
radiotherapy or chemotherapy. Some of the
patients had agreed to an adjuvant post-
operative treatment based on an active
specific immunotherapy schedule with chem-
ically modified CEA using 3 single injections
at Days 10, 40 and 130 after primary resection
(data to be published).
A computerized recall program was devel-
oped to keep contact with the patients. In
cases of death not registered in the clinic,
confirmation was obtained from the family
doctor, the relatives ofthe patient or the local
community administration.
Serum CEA concentrations were assayed
with the CEA-Roche-RIA test kit (Hoffman-
LaRoche, Basel, Switzerland) using only the
indirect method. When CEA concentrations
were >20 ,ug/l the sera were prediluted with
normal sera. Our own control sera were used
to standardize the CEA assay throughout the
investigation (Staab et al., 1980).
RESULTS
Exponential increases of serum CEA
could be detected retrospectively in the
postoperative courses of 48 patients who
did not consent to any treatment of their
recurrent disease. Generally recurrence
after colorectal carcinoma resection could
be predicted on the basis of consecutively
rising serum CEA levels. In most cases,
clinical confirmation and treatment of the
recurrence did not occur until several
months after the initial CEA rise. This
allowed the rate ofchange ofCEA levels to
be observed in 39 patients before therapy
ofrecurrent disease was commenced. In all
cases the linear portion of the graph
between log CEA and time covered a
sufficiently long period with at least 3
consecutive CEA determinations, merely
allowing a reliable calculation of the CEA
doubling time.
Patients with liver metastases
Most of our patients with recurrent
disease (59/87) had developed liver meta-
stases and 37/59 did not receive any
further treatment. The serum CEA of
these patients showed exponential in-
creases which, in many cases, were main-
tained until death. In the other cases the
CEA curves ended in a plateau with
occasional decreases or increases. In Fig.
1(a) the change ofserum CEA with time is
depicted and given as a semilogarithmic
plot in Fig. 1(b).
Individual CEA doubling times were
calculated for the 37 patients using the
periods of linear relationship between log
CEA and time. In Table I the CEADOUBLING TIME OF CIRCULATING CEA
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FIG. 1.-Time course of circulating CEA in
three patients with resected colorectal car-
cinoma developing liver metastasis: (a)
linear plot; (b) semi-log plot.
doubling times are listed for 33 patients
who developed liver metastasis but re-
ceived no further treatment and died. In
addition, the duration of the log CEA
phase and the time from the initial CEA
increase of the log phase until death are
given in days as well as in multiples of the
individual CEA doubling time for each
patient. The CEA doubling times ranged
from 10 to 102 days. It can be seen from
Table I that the survival time after the
initial log CEA rise increased with increas-
ing CEA doubling time. In Fig. 2 the CEA
doubling times of the 33 patients are
plotted against survival in days and a
positive correlation was obtained (r=
0.870). A correlation of the interval
between surgery and diagnosis with the
CEA doubling time was not observed.
Assuming that exponentially increasing
circulating CEA reflects directly growth of
liver metastases in man, the CEA doubling
time might represent a parameter to com-
pare the prognosis of individual patients.
When the survival times were expressed
on this relative scale. i.e. in multiples of
the individual CEA doubling times, it
should be noted that none ofthe untreated
patients with liver metastasis in Table I
survived longer than 10-8 CEA doubling
times after the initial CEA rise of the log
phase. Though the individual survival
periods ranged from 58 to 717 days, they
matched to a narrow range of 3-7-10*8
CEA doubling times with a mean of
7-0 + 1-8 CEA doubling times. This range
can be used as a reference parameter of
survival in all cases of liver metastases
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FIG. 2.-Correlation of CEA doubling time
with survival after the initial CEA increase
of patients (n = 33) who developed liver
metastasis after primary resection but
received no further treatment (correlation
coefficient r=0-870). The patients are the
same as listed in Table I.
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TABLE I.-CEA doubling times ofpatients who developed liver metastasis after resection
of the primary tumour but received nofurther treatment
Duration of log
CEA phase
CEA doubling
Days times (multiples)
69 6-9
32 2-9
54 4-5
52 4 0
42 2-6
88 3-8
98 4-1
142 5.5
141 4- 9
69 2-3
77 2-5
62 1-7
158 4-3
83 2-1
188 4-7
186 4-1
275 6-0
166 3-6
178 3-5
320 6-3
303 5-6
64 1-2
298 5-3
104 1-8
309 5 - 3
108 1-6
265 3-8
475 6- 6
215 2-7
306 3 - 6
144 1-6
512 5 - 7
406 4 0
Survival after initial
CEA increase
CEA doubling
Days times (multiples)
96 9-6
88 8-0
58 4-8
60 4-6
108 6-8
95 4-1
191 7 - 9
252 9- 7
214 7-4
325 10-8
262 8 -5
211 5-9
224 6-1
174 4-5
301 7-5
250 5 -6
320 7 0
314 6 -8
355 7 0
451 8-8
310 5- 7
478 8 - 7
459 8-2
460 8-1
557 9-6
558 8 - 3
366 5 -3
587 8-2
294 3-7
500 5 -8
441 5.0
581 6-5
717 7-0
Duration of the log CEA phase and survival after the initial CEA increase are given in days as well as in
multiples of the individual CEA doubling times
a s =sigmoid colon, c =colon, r = rectum.
irrespective of the site of the primary
carcinoma.
When the survival time after the initial
CEA rise, given in multiples of the
individual CEA doubling time, is a meas-
ure of development of liver metastases, it
should also represent an appropriate basis
to reflect any effect of treatment on the
survival of patients. Treatments generally
disturbed the log CEA/time correlation
and in Table II the CEA doubling times of
treated patients, their therapeutic modal-
ities and survival after the initial CEA rise
ofthe log CEA phase are listed. Only those
patients who had already died or who were
still alive despite more than 9 CEA
doubling times after the initial CEA rise
arerecorded. The latter are indicatedby >
in Table II. The comparison of the
survival times of treated (Table II) and
untreated patients (Table I) exhibiting
similar CEA doubling times indicates that
any treatment of recurrent disease poten-
tially increased the survival of patients.
When the survival periods of treated
patients were calculated as multiples of
individual CEA doubling times only 4/20
patients survived less than 10*8 CEA
doubling times. The mean survival of 16
treated patients who had already died was
17 4 + 9-4 CEA doubling times. This value
is distinctly higher (P < 0.001) than the
mean survival of untreated patients
(7.0 + 1.8 CEA doubling times). However,
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TABLE II.-CEA doubling times ofpatients who developed liver metastasis after
primary resection and underwent various postoperative treatments of recurrent disease
Duration of log
CEA phase
t A- I
Days
40
41
58
133
222
110
72
338
93
214
76
111
42
398
233
145
401
63
377
257
CEA
doubling
times
(multiples)
3-1
2-3
2 -4
5.3
6-7
3 -3
2-0
9 4
2-2
4-9
1-6
2 -4
0-9
8-0
4-4
2-7
5-1
0-8
4-3
2-9
Survival after initial
CEA increase
Days
> 720
729
>491
272
507
647
313
766
514
626
664
936
712
1089
489
1987
>794
784
> 843
819
CEA
doubling
times
(multiples)
>55.4
40-5
>20 5
10-9
15-4
19-6
8-7
21-3
12-0
14-2
14-1
19-9
15-1
21-7
9-2
36-8
>10-1
9-6
>9-6
9-2
Duration of the log CEA phase and survival of the patients are explained in Table I.
a For abbreviations see Table I.
b C = chemotherapy, I = immunotherapy, R = radiotherapy, 0= second look surgery, 00=second and
third look surgery.
c Immunization incomplete.
the standard deviation increased simul-
taneously which means that the various
treatments were not equally effective in
individual patients.
Patients with visceral and other metastases
Another group of patients with recur-
rent disease exhibiting exponential
increases of circulating CEA during recur-
rence had developed visceral metastases
other than liver metastases (20/87), brain
metastases (1/87) or bone metastases
(3/87). Selected CEA time courses and
their semilogarithmic plots are shown in
Fig. 3(a), (b).
Fourteen of these 24 patients received
treatment of recurrent disease or under-
went second-look surgery. In Table III the
CEA doubling times, the therapeutic
modalities and survival after the initial
CEA rise of the log CEA phase are given
for 20 patients. Patients under surveil-
lance for less than 9 CEA doubling times
but still alive are not includedin Table III.
In the 9 patients with untreated visceral
metastasis a correlation between CEA
doubling time and survival of patients
could not be established. Some of the
patients fitted the correlation plot given in
Fig. 2 for patients with liver metastasis.
This might be explained by the possibility
that a proportion ofpatients with visceral
metastases also had liver metastases not
readily detected by the clinical methods
used.
Though the question whether individual
CEA doubling times also correlate with
survival in the group of patients with
untreatedvisceral metastasisstill remained
open, it was found that the survival times
expressed in multiples of individual CEA
doubling times reflected quite accurately
the effect oftreatment on patient survival.
The mean survival after the initial CEA
rise of the log CEA phase was 43 + 2-3
CEA doubling times for patients without
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FIG. 3. Time course of circulating CEA in
patients with resected colorectal carcinoma
developing visceral metastasis ( x; ) or
second primary carcinomas (0; *): (a)
linear plot; (b) semi-log plot.
treatment, whereas the treated patients
had a mean survival of 96 + 4-2 CEA
doubling times (P = 0 003). In some cases,
the individual survival data indicated that
treatment of recurrent disease was not
very effective. The CEA doubling times
calculated from the CEA time courses of
patients who developed bone metastases
were relatively short. In the 3 cases
registered to date the CEA doubling times
were 54, 55 and 60 days. The CEA time
course of a patient who developed brain
metastasis exhibited a distinctly longer
CEA doubling time of 598 days.
Patients with local recurrence
To date we have registered 14 cases of
local recurrence exhibiting a log CEA
phase in the CEA time course. Six patients
underwent second-look surgery and 3/6
remained disease-free. All others showed
further disease progression and the corre-
sponding CEA time courses exhibited
biphasic log CEA slopes. The CEA time
courses of 2 selected cases are given in
Fig. 4. The calculated individual CEA
doubling times and the duration ofthe log
CEA phase of local recurrence are listed
together with the site of recurrence and
the diagnosis of disease progression (Table
IV). The CEA doubling times ranged from
142 to 868 days. Only the CEA doubling
time of a developing brain metastasis (598
days) was comparable with the higher
CEA doubling times oflocal recurrence. In
this special case local recurrence was
definitely excluded by a preceding
negative second-look operation.
DISCUSSION
The data obtained from our retrospective
study of the postoperative CEA time
courses of colorectal cancer patients with
recurrent disease disclosed two relation-
ships. (1) There were phases ofexponential
CEA increase during recurrent disease in
patients with resected colorectal car-
cinoma. Their establishment essentially
depended on the frequency of CEA
determinations performed. (2) There was a
positive correlation of CEA doubling time
and survival for colorectal cancer patients
who developed liver metastases without
having further treatment.
The question whether the phase oflinear
relationship between log CEA and time
correlates with a corresponding increase of
tumour volume in man as was observed in
nude mice xenografted with human
tumour cells (Raghavan et al., 1980; StaabDOUBLING TIME OF CIRCULATING CEA
TABLE III.-CEA doubling times of patients who developed metastasis other than liver
metastasis after primary resection and, in part, underwent various postoperative
treatments ofrecurrent disease
CEA
doubling
Primary time
Patients tumoura days
Visceral met.
1
2
3
4
5
6
7
8
9b
lOc
11
12
13
14
15
16
17
18
Brain met.
1
Bone met.
1
s
s
s
s
r
s
c
s
c
c
r
r
r
r
r
r
r
r
65
72
99
110
118
123
136
230
231
47
50
76
89
92
129
132
150
167
Duration of log
CEA phase
CEA
doubling
times
Days (multiples)
195
167
557
289
84
389
217
261
479
465
98
166
227
114
336
251
691
395
3 0
2-3
5-6
2-6
0 7
3 -2
1 -6
1-1
2-1
9-9
2-0
2 -2
2-6
1 -2
2-6
1-9
4-6
2-4
598 547 0 9
r
Survival after initial
CEA increase
CEA
doubling
times
Days (multiples)
330
603
739
408
309
461
367
473
571
622
754
975
>811
604
378
1509
1301
1000
5-1
8-4
7-5
3 -7
2-6
3.7
2-7
2-1
2-5
13-2
15-1
12-8
>9-1
6-6
2-9
11 -4
8-7
6-0
605 1.0
60 111 1-9 > 666 > 11.1
Duration of the log CEA phase and survival of patients are as in Table I.
a For abbreviations see Table I+11.
b Visceral and lung metastasis.
c Visceral and skin metastasis.
TABLE IV.-CEA doubling times ofpatients who developed local recurrences or second
primary carcinomas
Site of
recurrence
Sacral
Sacral
Sec. primary
Sec. primary
Sacral
Local
Sacral
Sec. primary
Local
Sacral
Sacral
Local
Local
Local
CEA
doubling time
days
142
144
168
221
251
258
264
272
328
356
362
736
770
868
Duration
of log CEA phase
days
176
225
420
133
156
274
522
371
98
414
363
190
282
218
Disease
progression
Visc. mets.
Visc. mets.
Liver mets.
Visc. mets.
Visc. mets.
Bone mets.
Bone Mets.
Disease freea
Liver mets.
Pelvis mets.
Disease freeb
Disease freee
Liver mets.
Bone mets.
a After second-look surgery for > 852 days.
b After second-look surgery for > 473 days.
c After immunotherapy, second-look surgery and chemotherapy for > 803 days.
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FIG. 4.-Bipliasic time course of circulating
CEA in patients with resected colorectal
carcinomas developing local recurrence
followed by visceral (0) or liver meta-
stasis (U): a linear plot; (b) semi-log plot.
& Anderer, 1981, 1982) remains presently
unanswered. The critical factor is the
release of CEA from the tumour cells and
the molecular mechanism by which it is
governed, since they determine the CEA
doubling times during the exponential
CEA increase. The fact that during
progressive increases of circulating AFP
and CEA a linear relationship between log
AFP or log CEA and time is observed,
implies that in these particular phases the
rates of release and degradation of these
tumour markers are relatively constant.
In this retrospective study we obtained
CEA doubling times in developing liver
metastases which ranged from 10 to 102
days. The individual CEA doubling times
correlated positively with survival of the
patients, calculated from the data ofinitial
log CEA increase, and the untreated
patients showed a mean survival of 7 0
individual CEA doubling times + 1-8. At
the beginning of the exponential increase
of circulating CEA and subsequently at
the time of diagnosis the patients usually
were symptom free, independent of CEA
doubling time. Assuming that the CEA
increase also correlated with tumour
volume in man, survival might be limited
by a critical tumour burden leading to
secondary complications in the liver.
Survival expressed in multiples of the
individual CEA doubling times also
proved toreflect directlythe effect oftreat-
ment of liver metastasis on tumour de-
velopment and survival.
For patients with visceral metastases
other than liver metastases and no further
treatment, a correlation between CEA
doubling time and survival could not be
established. This could be due to the
limited number ofpatients in this group or
more probably tothepossibilitythat CEA-
releasing cells in these metastatic cases
were not representative of the exacerba-
tion of malignant disease which might
entail tumour cells not releasing CEA.
Furthermore, the mean survival of these
patients, expressed in multiples of CEA
doubling times, were distinctly shorter
than for patients developing liver meta-
stasis possibly due to secondary complica-
tions leading to serious damage of normal
physiological functions earlier during
tumour development. In a recent report
(Toth et al., 1982) it was demonstrated
that CEA is rapidly removed from circula-
tion by the liver and therefore distinct
impairment of liver function might influ-
ence clearance of CEA giving rise to
shorter CEA doubling times.
The question whether the correlation
between CEA doubling times and survival
in patients with untreated liver metastasis
is based on CEA release from proliferating
metastatic cells or on failure of CEA
clearance by the liver or on both mech-DOUBLING TIME OF CIRCULATING CEA 781
anisms cannot be answered presently.
Further investigations on the biochemical
regulation of CEA release, degradation
and clearance are necessary.
The findings obtained in our retrospec-
tive study need confirmation by a prospec-
tive study randomized with respect to
other prognostic criteria including per-
formance status at the start of the
exponential CEA increase. However, since
CEA doubling times predicted survival in
colorectal cancer patients with liver meta-
stasis who were not treated, clinical trials
claiming improvements in overall survival
should be corrected for any imbalance in
distribution of CEA doubling times.
The authors thank Ms S. Glock and Ms S. Kraus
for excellent technical assistance.
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